医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nativis, Inc. Enters into Evaluation Agreement with Major Japan-Based Pharmaceutical Company

2016年08月03日 PM11:00
このエントリーをはてなブックマークに追加


 

SEATTLE

Nativis, Inc., a clinical stage life sciences company developing non-invasive, medical device therapies for cancers and other serious diseases, today announced that it has entered into an Evaluation Agreement with a major pharmaceutical company based in Japan. The core purpose of the Evaluation Agreement is to confirm the results of both In-Vitro and In-Vivo experiments that have been successfully completed by Nativis at independent research facilities in the United States.

The pharmaceutical company will conduct additional experiments in its labs. Both companies also plan to continue discussions around other potential business opportunities involving Nativis technologies and products in Japan.

“We are very pleased to enter into this agreement,” stated Chris Rivera, Nativis Chairman and Chief Executive Officer. “We look forward to their findings and to our ongoing conversations about other potential collaborations.”

About Nativis, Inc.

Nativis is a clinical stage bioelectronics company, based in Seattle, Washington, that develops non-invasive treatments for cancers and other serious diseases. Nativis utilizes its proprietary Radio Frequency Energy (RFE) technology which regulates defined bioactive targets by specific modulation of charge pathways. RFE modulated control of charge pathways has the potential to significantly change the way cancer and other serious diseases are treated.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160803005527/en/

CONTACT

Nativis, Inc.
Steven Pope, 206-708-2288 ext: 105
spope@nativis.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Konica Minolta and Innovation Network Corporation of Japan Close Acquisition of Ambry Genetics
  • Median Technologies Appoints Vivian Wang as General Manager, China and Takashi Hayashi as Managing Director, Japan
  • Second Sight Announces Appointments of Frank Vandeputte as Vice President and General Manager, EMEA and Asia Pacific; Gregoire Cosendai as Vice President, Clinical Affairs
  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″